SKINBIOTHERAPEUTICS PLC (SBTX) — Superdrug Commercial Agreement

Investor webinar replay

Replay transcript excerpt

Morning, ladies and gentlemen, and welcome to the SKINBIOTHERAPEUTICS PLC investor presentation. Of your screen. Please just simply type in your questions and press send. Given a significant attendance on today's call, the company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today, and we'll publish those responses where it's appropriate to do so. Before we begin, as usual, we would just like to submit the following poll. And if you could give that your kind attention, I'm sure the company would be most grateful. And I would now like to hand you over to the executive management team from SKINBIOTHERAPEUTICS PLC. Stuart, good morning, sir. Thank you, Jake. Good morning. Good morning, all. We have a short presentation to walk you through the recent super drug announcement. For those of you who are asking questions about Croda, we will cover that and the operating divisions briefly prior to a later presentation, which we'll give post year end once we've closed the accounts out where we will give trading update. So as an investment case, there's a single slide. As you can see, those of you know the company know all of this, but we do have a number of attendees who are new investors to the company. So for the benefit for their benefit, we are a strong science based company. The science initially came out of University of Manchester. It's a proprietary technology which takes live bacteria and turns it into a lysate, and I'll tell that in just a moment. That's to give basically skin barrier enhancement repair, how the skin looks, how it feels, and how it repairs itself. We are located in the Northeast Scientific cluster in Newcastle Pontine, and we have sales operations and d...